Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Ann Neurol. 2020 Dec 31;89(3):534–545. doi: 10.1002/ana.25981

Figure 3: Risk of Neurocognitive Impairment Associated with A)Cardiovascular or Pulmonary Conditions and B) Endocrine or Neurologic Conditions.

Figure 3:

The bars and error bars below represent odds ratios (OR) and 95% confidence intervals for the risk of neurocognitive impairment associated with any grade 2 or higher condition. The black dotted line represents the null reference association (OR=1, no grade 2 or higher condition). Logistic regression models are adjusted for age at diagnosis, gender, race, time since diagnosis, any high-dose cytarabine and cumulative dose of high-dose methotrexate. Central nervous system (CNS) models are further adjusted for neurosurgery, cumulative cranial radiation dose, and intrathecal methotrexate dose.